GlobeNewswire

YPO Global Pulse Survey: Which Disruptive Technologies Command Attention and Investment of CEOs Globally, Now?

Dela

https://editorial.globenewswire.com/ResourceLibrary/ResourceLibrary/GetDynamicThumbnailContentContent/?resourceId=bafdfc27-f81f-4632-86ba-c6cf838ac917&maxHeight=150&maxWidth=150

Survey of 10 disruptive technologies highlights those most likely to impact businesses and investments in the next 12 months

DALLAS, April 03, 2018 (GLOBE NEWSWIRE) -- YPO, the premier chief executive leadership organization in the world, announced today the results of the March 2018 YPO Global Pulse Survey, revealing that chief executives across the world are focused on core business technologies, such as cloud computing, business intelligence (BI) and cybersecurity, whilst adoption and investment of emerging technologies such as blockchain, artificial intelligence (AI) and cryptocurrency are likely to be sector-driven.

Disruptive Technologies Attracting CEO Attention and Likely Investment Globally:

  • Cloud computing is a key priority for chief executives globally - more than two-thirds (68%) of chief executives report that cloud computing is likely to impact their business in the next 12 months, and 62% state that they are likely to invest in cloud-based technologies.
     
  • Business Intelligence (BI) has the attention of CEOs - 65% of chief executives surveyed expect BI to impact their organizations and more than half (56%) are likely to invest in business intelligence in the coming 12 months.
     
  • Cybersecurity is a disruptive technology that chief executives have prioritized given the scale and severity of recent high-profile consumer data breaches, 53% of chief executives are expecting cybersecurity to impact their business and 47% state that they are likely to invest in cybersecurity technology in the coming year.

"What I'm hearing from YPO global business leaders right now is that digital transformation remains at the very top of their priorities in 2018. Several disruptive technologies are expected to garner widespread attention and investment this year, such as cloud computing, cybersecurity, business intelligence and mobile payment applications," said Scott Mordell, CEO of YPO. "YPO members are embracing technology to address regulatory requirements, harness business data for improved efficiency and increased financial performance, and to match consumer demand for new and innovative ways to interact with their businesses."

Despite Expected Disruption, CEOs Less Likely to Invest in These Technologies in the Next Year:

  • Although virtual reality (VR)/Augmented Reality (AR) are widely noted as technologies likely to impact most industries, most CEOs surveyed are not actively investing in those technologies yet. However, within architecture and engineering sectors, 83% of business leaders expect VR to impact their business and 64% plan to invest in it over the next 12 months, as compared to only 23% of all chief executives surveyed willing to invest in these technologies now.
  • Similarly, artificial intelligence (AI) is perceived as likely to impact businesses, but CEOs are less likely to invest in AI this year as cloud computing, business intelligence, cybersecurity and digital/mobile payment applications, which are commanding more immediate attention and likely candidates for investment in the next 12 months.
  • CEOs are least familiar with chatbot technology, followed by blockchain and cryptocurrency among the 10 disruptive technologies surveyed. As a result, they tend to discount the likelihood of disruption to their businesses from these new emerging technologies and show much lower interest in investing in these technologies this year.

Disruptive Technology Investment Driven by Specific Industry Sectors

The levels of familiarity and interest in many disruptive technologies are determined by industry.  For instance, although there has been much media attention and discussion around blockchain and cryptocurrency, most CEOs do not see either of those technologies as particularly likely to impact their businesses, and are not likely to invest in those technologies. However, blockchain has gained the attention and investment of CEOs in the financial services sector.

  • More than half (58%) of chief executives in financial services expect blockchain technology to impact their organization over the next 12 months, and as many as 40% expect to make investments in the technology.  
     
  • The Internet of Things (IoT) is cited as a key technology area by business leaders within the telecom, architecture, engineering and technology sectors. More than three quarters (78%) of chief executives in telecoms expect IoT to impact their business and almost all of them (96%) expect to make investments in IoT over the next 12 months.

"The findings of the YPO Global Pulse reveal that the short-term business impact and investment strategy associated with a particular technology is largely dependent on the specific industry in which you operate," noted Scott Mordell, CEO of YPO. "It will be fascinating to see how priorities and focus change over the next year as disruptive technologies such as AI and virtual reality become more mainstream."

YPO Global Pulse® Survey

The YPO Global Pulse provides insight into the perspectives of chief executives around the world on topics that influence businesses, leadership and impact. The March 2018 Global Pulse survey results provide key insight into the understanding, attitudes and investment plans of chief executives around the world, regarding the 10 disruptive technologies that are attracting attention right now. The March 2018 YPO Global Pulse survey provides perspectives from 842 YPO members, from 15 different regions of the world and across 28 industry sectors. Visit www.ypo.org/globalpulse for more information about the survey methodology and results.

About YPO

The premier leadership organization of chief executives in the world.

YPO is the global platform for chief executives to engage, learn and grow. YPO members harness the knowledge, influence and trust of the world's most influential and innovative business leaders to inspire business, personal, family and community impact.

Today, YPO empowers more than 25,000 members in more than 130 countries, diversified among industries and types of businesses. Altogether, YPO member-run companies employ more than 16 million people and generate USD6 trillion in annual revenues.

Leadership. Learning. Lifelong. For more information, visit YPO.org.

Contact:
YPO 
Linda Fisk
Office: +1 972 629 7305 (United States)
Mobile: +1 972 207 4298
press@ypo.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: YPO via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum